Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

Launched by NANTES UNIVERSITY HOSPITAL · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on collecting important health information from patients with lung cancer, specifically those newly diagnosed with different types of lung cancer, such as non-small cell lung cancer and small cell lung cancer. The goal is to gather real-world data that can help researchers understand how effective various treatments are for different patients, including those who might not typically be included in standard clinical trials. By following patients over time, the study aims to collect valuable information about their health, treatments, and response to therapies until they complete their treatment or the study ends.

To participate, patients need to be adults who have just been diagnosed with lung cancer and are receiving treatment at Nantes University Hospital. They must agree to take part in the study and provide consent. Healthy individuals can also join the study if they meet certain criteria, like not having any history of cancer or chronic diseases. Participants can expect to contribute to important research that may lead to better understanding and treatment options for lung cancer. This study will also involve collecting samples of blood and tumors, which can be used for future research to explore how cancer treatments work.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients :
• • Adult
• • Patient newly diagnosed with NSCLC or CPC
• • Cared for at Nantes University Hospital
• • Affiliated or beneficiaries of a social security scheme or similar
• • Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the absence of blinding).
• • Having agreed to participate in this study by signing the biocollection consent.
• Healthy subjects :
• • Adult
• • Affiliated or beneficiaries of a social security or similar scheme
• • Who have agreed to participate in this study by signing the Biocollection consent form.
• • No known infectious pathology
• • No known history of cancer
• • No known history of chronic autoimmune disease
• • No background immuno-suppressive treatment
• Ancillary Study :
• • -Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, either as monotherapy or in combination.
• Exclusion Criteria:
• Patients :
• • Previous anticancer treatment for Lung cancer
• • Patients who have not consented to participate in the BREATHE collection
• • History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
• • Inclusion in a therapeutic trial with blinded treatment
• • Patients under guardianship
• • Patients with AME.
• • Pregnant or breast-feeding women
• Healthy subjects :
• • Person under guardianship
• • Person benefiting from AME (State medical aid)
• • Pregnant or breast-feeding women
• Ancillary Study :
• • - Pregnant or breast-feeding women